Leerink Partners analyst Lili (Aurélie) Nsongo has reiterated their bullish stance on ARCT stock, giving a Buy rating on October 1.

Arcturus Therapeutics ARCT and partner CSL Seqirus, a renowned vaccine company, together reported encouraging results from a ...

CSL and Arcturus Therapeutics report that their sa-mRNA COVID-19 vaccine, ARCT-154, delivered superior immunogenicity ...

Arcturus Therapeutics Holdings Inc. ARCT is engaged in developing messenger RNA (mRNA) medicines and vaccines based on its innovative and enabling technologies. San Diego, CA-based Arcturus has ...

CSL Ltd. (CMXHF.PK) and Arcturus Therapeutics Holdings Inc. (ARCT), Monday announced that self-amplifying or sa-mRNA COVID-19 vaccine ...

A head-to-head study has revealed that CSL and Arcturus Therapeutic’s self-amplifying mRNA vaccine can maintain a stronger ...

Providing a diverse range of perspectives from bullish to bearish, 3 analysts have published ratings on Arcturus Therapeutics ARCT in the last three months. The table below summarizes their recent ...

On Wednesday, H.C. Wainwright maintained a positive outlook on Arcturus Therapeutics (NASDAQ:ARCT), reiterating a Buy rating and a $63.00 price target for the stock. The firm's stance comes after ...

CSL Limited (OTC:CSLLY) and Arcturus Therapeutics (NASDAQ:ARCT) announced the results of a Phase 3 head-to-head study of ARCT-154, a self-amplifying (sa-mRNA) COVID-19 vaccine, compared to Pfizer ...